BCAB News & Events

BioAtla files $200M mixed securities shelf

BioAtla and GATC Health announced a SPV transaction to advance ozuriftamab vedotin in a Phase 3 Study in 2L+ oropharyngeal squamous cell carcinoma/ As part of the SPV transaction, BioAtla will receive an initial $5M for general operating and 2L+ OPSCC clinical trial expenses from Inversagen AI, a newly formed company with a mission to cure age-related diseases. Inversagen AI was formed by GATC Health and Inversagen. The initial closing of the SPV transaction will occur concurrently with the initial closing of Inversagen AI'ss financing and is expected to occur by January 30, 2026, with the remaining $35M anticipated to close later in Q1 2026 when the Oz-V registrational clinical study is expected to begin, in each case subject to completion of financings by Inversagen AI and customary closing conditions. Inversagen AI will receive an aggregate 35% ownership stake in Oz-V, while BioAtla will retain 65% ownership across all Oz-V solid tumor indications after completion of the transaction. BioAtla and GATC Health also expect to collaborate with Inversagen AI for the research and development of CAB senolytic therapies with BioAtla maintaining rights to the cancer therapeutic applications of these new therapies.

"We remain on track for completing a partnership transaction by year end." said Jay Short, chairman, CEO and co-founder of BioAtla. "In addition, we've achieved FDA alignment on our Phase 3 registrational Oz-V trial design, and we continue to be encouraged by our CAB T-cell engagers progress with the achievement of the recent CAB-Nectin4-TCE milestone and the promising data from CAB-EpCAM-TCE, or BA3182, recently presented at ESMO."